728

Search Sites

Google

Monday, June 24, 2013

Overview of ELISA/Western blotting tests for HIV


HIV ELISA/Western blot is a set of blood tests used to diagnose chronic infection with human immunodeficiency virus (HIV).

How the Test is Performed
A blood sample is needed. For information on how this is done, see: Venipuncture.

How to Prepare for the Test
No preparation is necessary.

How the Test Will Feel
When the needle is inserted to draw blood, some people feel moderate pain, while others feel only a prick or stinging sensation. Afterward, there may be some throbbing.

Why the Test is Performed
Testing for HIV infection is done for many reasons, including:
  • Screening people who want to be tested
  • Screening people in high-risk groups (men who have sex with men, injection drug users and their sexual partners, and commercial sex workers)
  • Screening people with certain conditions and infections (such as Kaposi's sarcoma or Pneumocystis jirovecii pneumonia)
  • Screening pregnant women to help prevent them from passing the virus to the baby
  • When a patient has an unusual infection

Normal Results
A negative test result is normal. However, people with early HIV infection (termed acute HIV infection or primary HIV infection) often have a negative test result.

What Abnormal Results Mean
A positive result on the ELISA screening test does not necessarily mean that the person has HIV infection. Certain conditions may lead to a false positive result, such as Lyme diseasesyphilis, and lupus.
A positive ELISA test is always followed by a Western blot test. A positive Western blot confirms an HIV infection. A negative Western blot test means the ELISA test was a false positive test. The Western blot test can also be unclear, in which case more testing is done.
Negative tests do not rule out HIV infection. There is a period of time (called the "window period") between HIV infection and the appearance of anti-HIV antibodies that can be measured.
If a person might have acute or primary HIV infection, and is in the "window period," a negative HIV ELISA and Western blot will not rule out HIV infection. More tests for HIV will need to be done.

Risks
Veins and arteries vary in size from one patient to another and from one side of the body to the other. Obtaining a blood sample from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight but may include:
  • Excessive bleeding
  • Fainting or feeling light-headed
  • Hematoma (blood accumulating under the skin)
  • Infection (a slight risk any time the skin is broken)

Considerations
People who are at high risk (men who have sex with men, injection drug users and their sexual partners, commercial sex workers) should be regularly tested for HIV.
If the health care provider suspects early acute HIV infection, other tests (such as HIV viral load) will be needed to confirm this diagnosis, because the HIV ELISA/Western blot test will often be negative during this window period.

Alternative Names
HIV testing

References
Dewar R, Goldstein D, Maldarelli F. Diagnosis of human immunodeficiency virus infection. In: Mandell GL, Bennett GE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap 119.
Sax PE, Walker BD. Immunopathogenesis of human immunodeficiency infection. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007:chap 408.

Model Organisms


9      Mesoplasma florum:Genomic DNA      
14    Yeast PCR Protocols   
15    Yeast Genetics    
17    Yeast Culture and Storage       
18    Yeast Cellular Biology       
20    Arabidopsis Protocols        

Monday, June 10, 2013

Separation of normal CD34+ cells from fresh pheresis of mobilized stem cells




Separation of normal CD34+ cells from fresh pheresis of mobilized stem cells

1.      Resuspend sample up to 100 mL of MACS buffer (see recipe below). Aliquot to two 50-mL conical tubes. Centrifuge for 10 minutes at 1000 rpm to "soft spin" the pellet. A soft spin keeps the platelets, which are concentrated in pheresis samples, in the supernatant. Platelets cause major problems with the staining of the sample as well as the running of the sample through the magnetic column. The supernantant must be aspirated, not poured off, since the pellet is loose.
2.      If the supernatant from the soft spin is still relatively cloudy, the soft spin may be repeated.
3.      ACD-A changes the density of the cells in the pheresis sample so that granulocytes will stay at the interphase of the Ficoll. Although pheresis samples have a high concentration of granulocytes, it is more important to remove the platelets before they activate. An alternative protocol may be that the sample is initially suspended in buffer without ACD-A and then Ficolled. The mononuclear layer may then be resuspended in buffer with ACD-A, and the soft spin performed. We have found it best to just leave the granulocytes and adjust concentration of the antibody (follows).
4.      Count the total number of cells. Combine sample into one 50-mL conical tube. Miltenyi lists antibody amount according to the total number of cells; however, this may be adjusted according to the estimate of number of cells positive for the sorting parameter. Since pheresis has between 1-10% CD34+ cells, we usually use 50% of the recommended amount of antibody. If a Ficoll is not performed, this may be reduced to ? the amount of antibody, but the buffer should not go below ?, and the incubation time should be extended to 30 minutes. Add ? the amount of buffer recommended by Miltenyi. Add ? the amount of reagent A1, shake gently. Add ? the recommended amount of reagent A2, shake gently. Incubate in the refrigerator for 15 minutes, gently shaking the sample periodically.
5.      Wash the sample two times with 50 mL of MACS buffer.
6.      Resuspend the sample in _ the recommended amount of buffer, and _ the amount of reagent B, shake gently. Incubate in the refrigerator for 15 minutes, gently shaking the sample periodically.
7.      Wash the sample one time with 50 mL of MACS buffer.
8.      Resuspend the sample in at least 10 mL degassed (see Note) MACS buffer for 1 x 109 total cells, or up to 20 mL for 2 x 109 total cells. Run sample over a VS positive selection column.
9.      Wash 2X with 3 mL of degassed buffer.
10.   Attach stop cock and syringe to bottom of VS column. Remove column from magnet. Backflush column with 6 mL of degassed buffer. Replace column in magnet.
11.   Remove stop cock. Allow buffer to flow through column. Wash 2X with 3 mL of buffer.
12.   Remove column from magnet. Add 6 mL buffer to column and allow to run through. Add 6 mL buffer to column and plunge the column.
13.   Count the total number of cells collected from each fraction to calculate the recovery of the separation.
14.   Perform flow cytometry on the collected fractions to assess sample purity with CD45-FITC and CD34-PE (Becton Dickinson).

MACS buffer
Hank's Balanced Saline Solution (HBSS) -Ca+2, -Mg+2
0.5% BSA
0.6% Anticoagulant Citrate Dextrose- Formula A (ACDA) (Baxter)
Filter sterilize and store at 4°C

Notes: It is very important when running the magnetic column that only degassed MACS buffer be used. To degas the buffer, place 100 mL of buffer in a 150-mL bottle. Place a rubber stopper attached to a vacuum line over the mouth of the bottle. Turn vacuum on. Allow the buffer to degas at room temperature for at least 30 minutes. Replace cap on bottle and refrigerate buffer until cold. Use buffer as directed.

Mouse Tumor Biology (MTB) Database


The Mouse Tumor Biology (MTB) Database supports the use of the mouse as a model system of hereditary cancer by providing electronic access to:

l  Information on endogenous spontaneous and induced tumors in mice, including tumor frequency & latency data,
l  Information on genetically defined mice (inbred, hybrid, mutant, and genetically engineered strains of mice) in which tumors arise,
l  Information on genetic factors associated with tumor susceptibility in mice and somatic genetic-mutations observed in the tumors,
l  Tumor pathology reports and images,
l  References, supporting MTB data
l  Links to other online resources for cancer

http://tumor.informatics.jax.org/mtbwi/index.do

Biotech News

Powered by Feedzilla